Abstract
A comparative investigation of the antineoplastic activity of adriamycin and its derivative, N-trifluoroacetyladriamycin-14-valerate (AD 32), was conducted in murine tumor models employing different treatment schedules and injection routes. In all conditions tested, i.e., ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia.
| Original language | English |
|---|---|
| Pages (from-to) | 111-117 |
| Number of pages | 7 |
| Journal | Cancer Treatment Reports |
| Volume | 62 |
| Issue number | 1 |
| Publication status | Published - 1978 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate. / Vecchi, A.; Cairo, M.; Mantovani, A.; Sironi, M.; Spreafico, F.
In: Cancer Treatment Reports, Vol. 62, No. 1, 1978, p. 111-117.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate
AU - Vecchi, A.
AU - Cairo, M.
AU - Mantovani, A.
AU - Sironi, M.
AU - Spreafico, F.
PY - 1978
Y1 - 1978
N2 - A comparative investigation of the antineoplastic activity of adriamycin and its derivative, N-trifluoroacetyladriamycin-14-valerate (AD 32), was conducted in murine tumor models employing different treatment schedules and injection routes. In all conditions tested, i.e., ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia.
AB - A comparative investigation of the antineoplastic activity of adriamycin and its derivative, N-trifluoroacetyladriamycin-14-valerate (AD 32), was conducted in murine tumor models employing different treatment schedules and injection routes. In all conditions tested, i.e., ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia.
UR - http://www.scopus.com/inward/record.url?scp=0018181271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018181271&partnerID=8YFLogxK
M3 - Article
C2 - 626989
AN - SCOPUS:0018181271
VL - 62
SP - 111
EP - 117
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
SN - 0361-5960
IS - 1
ER -